However, most patients (80–85%) with BC are HER2-negative (defined by an IHC staining score of 0 and 1+ or an IHC staining score of 2+ with negative ISH findings)6, for whom these anti-HER2 therapies are not efficacious5. The gene discussed is ERBB2; the disease is breast cancer.